GlassScriptPhysician profile
Christy Lemon
NPI 1043979248
$915.41
in general payments reported to CMS, 2019-2025
25 companies · $14.23 in 2025
The $14.23 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $606 · 2024: $72.70 · 2025: $14.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $161.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $122.48 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $60.29 | 2023 | Calquence, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $50.83 | 2023 | Imbruvica, Erleada |
| Exelixis INC. | $42.62 | 2023-2024 | Cabometyx |
| Seagen INC. | $42.38 | 2022-2023 | Adcetris |
| Beigene USA, INC. | $42.07 | 2023-2024 | Brukinsa |
| Incyte Corporation | $35.81 | 2023 | Monjuvi |
| Mylan Institutional INC. | $34.25 | 2022-2023 | Fulphila, Ogivri |
| Taiho Oncology, INC. | $27.30 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $27.10 | 2023 | Epkinly |
| Jazz Pharmaceuticals INC. | $26.72 | 2023 | |
| Progenics Pharmaceuticals, INC. | $24.17 | 2023 | Pylarify |
| Sun Pharmaceutical Industries INC. | $21.70 | 2023 | Yonsa, Odomzo |
| Sobi, INC | $21.03 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.75 | 2023 | Libtayo |
| Merck Sharp & Dohme LLC | $19.80 | 2023 | Keytruda |
| Mirati Therapeutics, INC. | $19.76 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $19.03 | 2023 | |
| Genentech USA, INC. | $18.55 | 2023 | Polivy, Tecentriq |
| Karyopharm Therapeutics INC. | $18.19 | 2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $16.17 | 2023 | Ninlaro |
| Emd Serono, INC. | $15.24 | 2023 | Bavencio |
| Abbvie INC. | $14.23 | 2025 | |
| Stemline Therapeutics INC. | $13.37 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Lemon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.